Dantari, Inc.
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer (NCT05261269) | Dantari, Inc. | 2022-02-02 |
Track Dantari, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.